The researchers determined that because the incidence rate was so low, GLP-1 use was not associated with a substantially increased risk of developing thyroid cancer, though they couldnt exclude a small increase in risk. The study also did a secondary analysis comparing 111,744 patients who took GLP-1 drugs to 149,179 patients who took another form of diabetes drug called SGLT2 inhibitors, and the results were consistent with the DPP4 inhibitor comparison
5a), confirming successful genome editing via LNP-mediated HITI
The future of multi-receptor weight loss compounds The competition between retatrutide and semaglutide represents something larger than two compounds vying for market share
Mazdutide (IBI362, LY3305677, CAS 2259884-03-0) is a synthetic 39 amino acid long-acting oxyntomodulin analog and unimolecular dual agonist of GLP-1R and GCGR
However, they are manageable with dietary and lifestyle modifications or with dose adjustments